Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ALK rearrange BRAF V600E |
| Therapy | Alectinib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK rearrange BRAF V600E | lung non-small cell carcinoma | predicted - resistant | Alectinib | Case Reports/Case Series | Actionable | In a retrospective analysis of a Phase III trial (J-ALEX), BRAF V600E was identified in the post-progression cell-free DNA of a patient with non-small lung cancer with ALK rearrangement who progressed on treatment with Alecensa (alectinib) (PMID: 40912045). | 40912045 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40912045) | Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study. | Full reference... |